HE4 as a biomarker for diagnosis of lung cancer
A meta-analysis
Yong-Peng He, MDa,b, Li-Xian Li, MDa, Jia-Xi Tang, MDa, Lin Yi, MDa, Yi Zhao, MDa, Hai-Wei Zhang, MDa, Zhi-Juan Wu, MDa, Hai-Ke Lei, MDa, Hui-Qing Yu, MDa, Wei-Qi Nian, MDa,b, Lin Gan, MDa,b

Abstract

Background: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice.

Methods: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3.

Results: There were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12–26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83–0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73–0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79–0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77–1.00).

Conclusions: HE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future.

Abbreviations: AUC = area under the curve, CI = confidence interval, CMIA = chemiluminescent microparticle immunoassay, DOR = diagnostic odds ratio, ECLA = electro-chemiluminescence immunoassay, ELISA = enzyme-linked immunosorbent assay, FN = false negative, FP = false positive, HE4 = human epididyms protein 4, LDCT = low-dose computed tomography, NLR = negative likelihood ratio, NSCLC = nonsmall cell lung cancer, PLR = positive likelihood ratio, QUADAS = Quality Assessment of Diagnostic Accuracy Studies, SCLC = small cell lung cancer, SROC = summary receiver-operating characteristic, TN = negative, TP = true positive.

Keywords: biomarker, diagnosis, HE4, lung cancer, meta-analysis
1. Introduction

Lung cancer is one of the most common cancers in China and worldwide, and it is also one of the leading causes of cancer mortality in both males and females.\[1–4\] This disease is typically diagnosed at an advanced stage, and the 5-year net survival is 10% to 20% in most countries.\[4\] Due to this high mortality, early detection may be a valuable approach to detect the disease at an earlier, asymptomatic, and potentially curable stage. Lung cancer may potentially be diagnosed at an early stage among high-risk individuals through the use of screening with low-dose computed tomography (LDCT), which can reduce lung cancer-related mortality. However, the positive outcome may generate new issues related to the rate of overdiagnosis of indolent cancer.\[5\] Furthermore, people screened for lung cancer with LDCT comprise a small proportion.\[6\] Currently, some serum tumor markers, such as carcinoembryonic antigen, squamous cell carcinoma-associated antigen, cytokeratin-19 fragment, neuron-specific enolase, and pro-gastrin-releasing peptide, can significantly improve the diagnosis of lung cancer, but specific markers are still lacking.\[7–9\]

Human epididymis protein 4 (HE4), encoded by the WAP 4-disulfide core domain 2 (WFDC2) gene, is a promising biomarker for ovarian cancer.\[10\] This molecule has been approved by the US Food and Drug Administration for use in the United States to monitor ovarian cancer for disease recurrence, differential diagnosis, and malignancy likelihood assessment in women with a pelvic mass.\[11,12\] In recent years, an increasing number of clinical studies have shown that HE4 has a high diagnostic capacity for lung cancer.\[13–23\] However, studies on HE4 are mostly from individual research centers, and the results of evidence-based medicine from different research centers are lacking. Therefore, we conducted a meta-analysis based on relevant and available studies to assess the value of serum HE4 for diagnosing lung cancer and provide reliable scientific conclusions to guide clinical practice.

2. Methods

2.1. Search strategy and study selection

A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical
Literature, and WANFANG databases was conducted to identify relevant studies published up to June, 2017. The search strategy used both medical subject heading terms and free-text words to increase the sensitivity of the search. The search words were as follows: (“HE4” or “human epididymis protein 4” or “whey-acidic-protein four-disulfide core protein 2” or “WFDC2”) and (“nsclc” or “non-small cell lung cancer” or “non-small cell lung carcinoma” or “lung carcinoma” or “lung squamous cell carcinoma” or “adenocarcinoma of lung” or “squamous cell carcinoma of lung” or “lung cancer” or “lung neoplasms” or “lung tumor”). Papers published in English and Chinese were included in our study. Authors of trial reports published only as abstracts and with incomplete data were contacted and asked to contribute full datasets or completed papers. Additionally, the bibliographies of all identified relevant studies were manually reviewed to potentially identify any additional studies that may have been missed by the electronic search. The strategy used for PubMed is shown in Supplementary Data 1, http://links.lww.com/MD/D240.

Two investigators independently assessed the publication titles, abstracts, and full-text articles using predesignated eligibility forms according to the eligibility criteria. Any disagreement between investigators was resolved through consensus with a third investigator.

2.2. Study inclusion and exclusion criteria

In our meta-analysis, eligible studies had to meet the following standards: serum HE4 was used to detect patients with lung cancer as the case group and patients with benign lung diseases and/or healthy individuals as the control group; data such as the true positive (TP), false positive (FP), false negative (FN), and true negative (TN) were available in the studies; the measurement of serum HE4 must use commercial reagents; the literature reviewed was published in Chinese or English; if there were duplicate data, we chose the most complete data or the most recent data; the cut-off level must be presented. Excluded were the following standards: papers from which the extracted data were not sufficient; review articles, meta-analyses, meeting abstracts, case reports, and systematic reviews, and also preclinical studies; Studies with ambiguous diagnostic criteria.

2.3. Data extraction and quality assessment

All data were extracted independently from the studies by 2 investigators, including study characteristics (first author, publication year, country, assay method, type of cancer, cut-off point), and number of samples and outcome data (TP, FP, FN, and TN). The methodological quality of each trial was evaluated by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool and Review Manager 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, 2014). According to the Cochrane guidelines, high, unclear, or low risk of bias of the patient selection, index tests, reference standards, and flow and timing domains were evaluated. Applicability concerns in the patient selection, index tests, and reference standards were also evaluated.

2.4. Statistical analysis

A bivariate regression model was used to calculate the pooled sensitivity, specificity, negative likelihood ratio (NLR), positive likelihood ratio (PLR), diagnostic odds ratio (DOR), area under the curve (AUC), and associated 95% confidence intervals (CIs). Spearman rank correlation analysis was used to test the threshold effect. Inconsistency index ($I^2$), a chi-square test, and a bivariate box-plot were used to assess heterogeneity. Studies with an $I^2$ statistic of 25% to 50% were considered to have low heterogeneity, those with an $I^2$ statistic of 50% to 75% were considered to have moderate heterogeneity, and if $I^2 > 75\%$, high heterogeneity was considered to exist in the studies. A random-
effects model was used for the meta-analysis if heterogeneity was present. Otherwise, a fixed-effects model was applied. In addition, to investigate the potential effect of heterogeneity, we carried out meta-regression and subgroup analyses. We used a likelihood ratio scatter-gram to evaluate the confirmation and exclusion capacities of HE4. A Fagan diagram was employed to calculate the post-test probability. Finally, Deek funnel plot was used to assess the publication bias. All statistical analyses were performed using STATA software (STATA version 12.0, Stata Corporation).

3. Results

3.1. Literature research and characteristics of the studies

A total of 228 literature citations were identified by the initial database search, and 3 citations were identified through other sources. A total of 93 records were excluded because of duplicate studies, and 95 records were excluded based on titles and abstracts. The remaining 43 full-text articles were reviewed for a more detailed evaluation, and 22 of them were also excluded because 1 article was a conference abstract, 3 articles were duplicate data, 7 articles did not provide data, and 11 articles did not meet the inclusion criteria. Finally, 21 studies that met the inclusion criteria were included in our meta-analysis. The flow chart of the study selection process is shown in Fig. 1.

The major characteristics of the included studies are shown in Table 1. There were 3579 samples from 6 different countries included in our meta-analysis involving 1883 cases and 1696 controls. The sample size ranged from 70 to 434. All studies were published between 2012 and 2017. A total of 10 studies were published in English, and 11 were published in Chinese. Four studies examined a Caucasian population, and 17 studies had an Asian population. The HE4 cut-off levels were reported in these studies with different units. Three different methods were used to detect the level of HE4: 9 of the 21 studies used enzyme-linked immunosorbent assay (ELISA); chemiluminescent microparticle immunoassay (CMIA) were used in 4 studies; and 8 studies used electro-chemiluminescence immunoassay (ECLIA).

3.2. Quality assessment

According to QUADAS-2, the methodological quality assessment of each trial is shown in Fig. 2. The risk of bias in patient selection was high in 5 studies. Three studies were shown to have a high bias in their index tests, and only 1 had a high bias in the reference standard. Seventeen studies were found to have a low bias in their flow and timing. Three studies showed a high bias in patient selection in the applicability concern, 2 studies were shown to have a high bias in the index test, and only 1 study showed a high bias in the reference standard. The assessment of the quality of most of the included studies was not bad, but some studies were evaluated as high risk in patient selection, index test, reference standard, flow and timing for risk, and bias or applicability concern, which might impact the pooled effects.

3.3. Meta-analysis

The $I^2$ of 98 (95% CI 97–99), chi-square test ($Q=119.859$, $P=.000$), and a bivariate box-plot (Fig. 3) indicated that
significant heterogeneity was present. Therefore, a random-effects model was performed for the meta-analysis in our study. The Spearman correlation coefficient was -0.54 (P=.29), suggesting that there was no significant threshold effect. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% CI 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively (Fig. 4). The PLR and NLR were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively (Fig. 5). The DOR was 17 (95% CI 12–26). The AUC of the SROC was 0.86 (95% CI 0.83–0.89) (Fig. 6). According to the likelihood ratio scattergram, the confirmation and exclusion capacities of HE4 for diagnosing lung cancer were limited (Fig. 7). As shown by the Fagan diagram, the post-test probability corresponding to PLR and NLR was 57% and 7%, which differed substantially from the pretest probability (20%) (Fig. 8). To assess the publication bias for the diagnostic, we used Deek’s funnel plot asymmetry test. There was no obvious asymmetry in the funnel plot, indicating no significant publication bias in this meta-analysis (P=0.17) (Fig. 9).

3.4. Meta-regression and subgroup analyses

Because heterogeneity existed in our study, univariable meta-regression and subgroup analyses were carried out to investigate potential sources of heterogeneity. Race, assay method (ELISA, ECLIA), type of cancer (SCLC and NSCLC), sample size, and publication date were included in the meta-regression analysis of sensitivity and specificity (Fig. 10). The forest plot of the univariable meta-regression indicated that race, assay method (ELISA, ECLIA), type of cancer (SCLC and NSCLC), sample size, and publication date may be the sources of the heterogeneity in the sensitivity, whereas assay method (ELISA, ECLIA), type of cancer (NSCLC), and publication date may be the sources of the heterogeneity in the specificity in our meta-analysis.

Race, assay method, and type of cancer were included in the subgroup analyses (Table 2). The sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). Regarding the assay method, when CMIA was used to detect HE4, the sensitivity was the highest at 0.79 (95% CI 0.73–0.97). When the ELISA was used, the specificity was the highest at 0.87 (95% CI 0.79–0.94). For the type of cancer, when HE4 was used to diagnose NSCLC, the sensitivity was highest at 0.79 (95% CI 0.73–0.97), whereas the specificity was highest in small cell lung cancer (SCLC) at 0.90 (95% CI 0.77–1.00).

4. Discussion

Human epididymis protein 4—a promising biomarker—has been commonly used in many malignant tumors, especially in ovarian cancer. The sensitivity and specificity of HE4 was higher than that of cancer antigen 125 as a tumor marker for ovarian cancer. The sensitivity and specificity of HE4 could be used to diagnose lung cancer. However, to assess the value of HE4 for diagnosing lung cancer, the data of...
Evidence-based medicine from different research centers should be subjected to pooled analysis. The impact of race, assay method, and type of lung cancer should be determined. The present meta-analysis showed that HE4 was highly useful for the differential diagnosis of lung cancer with good sensitivity and specificity, and it was a potential serum tumor marker.

A previous meta-analysis involving only 715 cases and 549 controls from 7 studies indicated that serum HE4 is a potential marker for lung cancer diagnosis.[37] Using the previous meta-analysis as a base, we included 3579 samples from 21 studies in our meta-analysis involving 1883 cases and 1696 controls. The sample size increased nearly 3-fold compared with that of the previous meta-analysis. Moreover, 13 studies, including the present meta-analysis, were published after 2014. Therefore, the evidence on HE4 for diagnosing lung cancer in our study was strong. It was unfortunate that the source of heterogeneity was not detected because the number of eligible studies was limited in the previous meta-analysis. Our study addressed this issue to a degree.

To investigate potential sources of heterogeneity, we performed univariable meta-regression and subgroup analyses. Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. The sensitivity and specificity were investigated between Asian and Caucasian populations. The sensitivity of Caucasians for HE4 in diagnosing lung cancer was higher than that of Asians. Nevertheless, the specificity was better in Asians than Caucasians. Therefore, the diagnostic performance may be improved when using HE4 as a serum tumor marker.
Human epididymis protein 4 had a high sensitivity and specificity according to the present study. The Fagan diagram and the likelihood ratio scatter-gram revealed the clinical application value of HE4 for diagnosing lung cancer, although its application was limited in our study. The SROC has been recommended to assess the performance of a diagnostic test in a meta-analysis. Our meta-analysis found that the AUC of the SROC was 0.86 (95% CI 0.83–0.89), also demonstrating that HE4 was a potential biomarker for lung cancer diagnosis.
Table 2: Subgroup analyses of race, assay method, and type of cancer.

| Subgroup                | No. of trials | No. of patients | Sensitivity (95% CI) | Specificity (95% CI) |
|-------------------------|---------------|----------------|----------------------|----------------------|
| Race                    |               |                |                      |                      |
| Asian                   | 17            | 3063           | 0.71 (0.66–0.77)     | 0.87 (0.81–0.92)     |
| Caucasian               | 4             | 516            | 0.81 (0.71–0.91)     | 0.85 (0.73–0.97)     |
| Assay method            |               |                |                      |                      |
| ELISA                   | 9             | 1633           | 0.76 (0.68–0.83)     | 0.87 (0.79–0.94)     |
| CMIA                    | 4             | 571            | 0.79 (0.69–0.89)     | 0.86 (0.74–0.97)     |
| ECLIA                   | 8             | 1375           | 0.67 (0.58–0.76)     | 0.86 (0.79–0.94)     |
| Type of cancer          |               |                |                      |                      |
| SCLC and NSCLC          | 12            | 2310           | 0.70 (0.63–0.76)     | 0.89 (0.84–0.94)     |
| NSCLC                   | 7             | 1061           | 0.79 (0.72–0.87)     | 0.79 (0.68–0.89)     |
| SCLC                    | 2             | 208            | 0.74 (0.57–0.91)     | 0.90 (0.77–1.00)     |

CI = confidence interval, CMIA = chemiluminescent microparticle immunoassay, ECLIA = electrochemiluminescence immunoassay, ELISA = enzyme-linked immunosorbent assay, NSCLC = nonsmall lung cancer, SCLC = small cell lung cancer.

Figure 10. Forest plot of meta-regression and subgroup analyses of sensitivity and specificity for HE4 in diagnosing lung cancer. (A) Asian; (B) Caucasian; (C) total patients ≥150 cases; (D) total patients <150 cases; (E) publication year ≥2014; (F) publication year <2014. HE4 = human epididymis protein 4, NSCLC = nonsmall cell lung cancer, SCLC = small lung cancer.
The present meta-analysis included 3579 samples from 21 studies obtained through a comprehensive search strategy. Meta-regression and subgroup analyses were performed to investigate sources of heterogeneity. However, our meta-analysis also had limitations. First, only papers published in English and Chinese were included in our meta-analysis, so articles in other languages may have been excluded, leading to unavoidable bias. Second, we did not evaluate the diagnostic value of HE4 for different stages of lung cancer for the lacking about this field. Further studies should focus on this issue. Third, there was no unified cut-off level, which was a limitation of the present meta-analysis. Finally, some studies included in our meta-analysis were evaluated as high risk in patient selection, index test, reference standard, flow and timing for risk, and bias or applicability concern, which might impact the results of our study.

5. Conclusions

The current study showed that HE4 was a relatively promising and effective biomarker for discriminating lung cancer patients from healthy individuals and benign lung disease patients, especially for SCLC. Furthermore, the diagnostic performance differed depending on the different assay method. CMIA had the highest sensitivity, and ELISA had the highest specificity. However, it is necessary to perform more large-scale and well-designed studies to confirm our conclusion.

Author contributions

Conceptualization: Wei-qi Nian, Lin Gan.
Data curation: Yong-peng He, Lin Yi, Yi Zhao, Lin Gan.
Formal analysis: Yong-peng He, Hai-ke Lei.
Funding acquisition: Zhi-juan Wu, Hui-qing Yu.
Investigation: Hai-wei Zhang.
Project administration: Jia-xi Tang, Lin Gan.
Resources: Zhi-juan Wu.
Software: Li-xian Li.
Supervision: Lin Gan.
Validation: Wei-qi Nian.
Writing – original draft: Yong-peng He.
Writing – review & editing: Wei-qi Nian.

References

[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
[2] Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China in 2013: an analysis based on urbanization level. Chin J Cancer Res 2017;29:1–10.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30.
[4] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023–37.
[5] Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:i1–21.
[6] Jemal A, Fedewa SA. Lung cancer screening with low-dose computed tomography in the United States: 2010 to 2015. JAMA Oncol 2017;3:1278–81.
[7] Molina R, Marrades RM, Auge JM, et al. Assessment of a combined panel of six serum tumor markers for lung cancer. Am J Respir Crit Care Med 2016;193:9427–37.
[8] Jiang ZF, Wang M, Xu J. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci 2018;194:1–6.
[9] Nakamura H, Nishimura T. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer. Surg Today 2017;47:1037–9.
[10] Hellstrom I, Raycrafl J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–700.
[11] Wu L, Dai ZY, Qian YH, et al. Diagnostic evaluation of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer 2012;22:1106–12.
[12] Chang X, Ye X, Dong L, et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer 2011;21:852–8.
[13] Wojcik E, Tarapacz J, Rychlík U, et al. Human epididymis protein 4 (HE4) in patients with small-cell lung cancer. Clin Lab 2016;62:1625–32.
[14] Dikmen E, Gungor A, Dikmen ZG, et al. Diagnostic efficiency of he4 and cyfra 21-1 in patients with lung cancer. UHOD 2015;25:44–50.
[15] Huang W, Wu S, Lin Z, et al. Evaluation of HE4 in the diagnosis and follow up of non-small cell lung cancers. Clin Lab 2017;63:461–7.
[16] Iwahori K, Suzuki H, Kishi Y, et al. Serum HE4 as a diagnostic and prognostic marker for lung cancer. Tumour Biol 2012;33:1141–9.
[17] Liu W, Yang J, Chi PD, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis 2013;17:1346–53.
[18] Nagy BJ, Bhattachar PW, Steiber Z, et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med 2014;52:1639–48.
[19] Ucar EY, Ozkaya AL, Araz O, et al. Serum and bronchial aspiration fluid HE-4 levels in lung cancer. Tumour Biol 2014;35:8795–9.
[20] Wang X, Fan Y, Wang J, et al. Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer. Tumour Biol 2014;35:6847–53.
[21] Yamashita S, Tokuiishi K, Moroga T, et al. Serum level of HE4 is closely associated with pulmonary adenocarcinoma progression. Tumour Biol 2012;33:2365–70.
[22] Yoon HI, Kwon OR, Kang KN, et al. Diagnostic value of combining tumor and inflammatory markers in lung cancer. J Cancer Prev 2016;21:187–9.
[23] Zeng Q, Liu M, Zhou N, et al. Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer. Clin Chim Acta 2016;455:102–6.
[24] Yang Z, Wei C, Luo Z, et al. Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis. Onco Targets Ther 2015;8:957–66.
[25] Li LM, Zhu YX, Zhong Y, et al. Human epididymis protein 4 in endometrial cancer: a meta-analysis. Clin Chim Acta 2018;482:215–23.
[26] Cheng D, Sun Y, He H. The diagnostic accuracy of HE4 in lung cancer: a meta-analysis. Dis Markers 2015;2015:352670.
[27] Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer 2017;17:725–37.
[28] Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002;21:1237–56.
[29] Biijiang P, Rong C. Diagnostic value of human epididymis protein 4 combined with CA125 for lung cancer. J Clin Res 2017;34:563–70.
[30] Haddong L, Xiao peng T. Diagnostic value of human epididymis protein 4 in lung cancer. Chin J Clin Lab Sci 2015;33:285–6.
[31] Jian Z, Xin-Min D, Jing W, et al. The diagnostic value of human epididymis protein 4 in lung cancer. Chin J Clin Lab Sci 2015;33:285–6.
[32] Jin J, Lin Y, Yong-biao L. Clinical value of serum and bronchial aspiration fluid HE-4 levels in patients with lung cancer. J Hainan Med Univ 2016;22:169–71.
[33] Xin W, Bi W, Guoqiang X, et al. The diagnostic value of human epididymis protein 4 for lung cancer. Int J Lab Med 2015;21:3188.
[35] Yang Z, Fang D, Ming L, et al. Diagnostic value of serum human epididymal protein 4 in male for lung adenocarcinoma. Chin J Clin Lab Sci 2016;34:40–1.

[36] Yigong Z, Yan Z, Long J, et al. The prognostic value of serum HE4 in lung cancer. Chin J Radiol Med Prot 2014;6:423–6.

[37] Ying W, Pei-zhang L, Wen-cheng H, et al. Diagnostic value of serum HE4, NSE and CYFRA21-1 levels for lung cancer patients. J Clin Pulmon Med 2016;12:2159–61.

[38] Zhenghong L, Zhengqiu Z, Chengxi Y, et al. Clinical significance of serum human epididymis protein 4 detection in the diagnosis of non-small cell lung cancer. Chin J Clin Oncol Rehabil 2016;23:1413–6.

[39] Ping Z, Hongxing Z, Yang B, et al. Significance on the combined detection of human epididymis protein 4 and CYFRA21-1 in the diagnosis of non-small cell lung cancer. Lab Med 2014;12:1215–7.